| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dimopoulos Christos | Executive VP, Global Markets | C/O BUNGE GLOBAL SA, 1391 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD | /s/ Drew Yaeger, Attorney-in-Fact | 25 Nov 2025 | 0001758115 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BG | Common Stock | Options Exercise | $265K | +5.3K | +4.26% | $50.07 | 130K | 21 Nov 2025 | Direct | |
| transaction | BG | Common Stock | Sale | -$500K | -5.3K | -4.08% | $94.38 | 125K | 21 Nov 2025 | Direct | F1 |
| transaction | BG | Common Stock | Sale | -$1.89M | -20K | -16.06% | $94.37 | 105K | 21 Nov 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BG | Stock Options (Right to buy) | Options Exercise | $0 | -5.3K | -100% | $0.00 | 0 | 21 Nov 2025 | Common Stock | 5.3K | $50.07 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | This transaction was executed in multiple trades at prices ranging from $94.30 to $94.48. The price reported reflects the weighted average sale price. The reporting person undertakes to provide to Bunge Global SA, any security holder of Bunge Global SA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
| F2 | This transaction was executed in multiple trades at prices ranging from $94.28 to $94.44. The price reported reflects the weighted average sale price. The reporting person undertakes to provide to Bunge Global SA, any security holder of Bunge Global SA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
| F3 | This option became exercisable in three equal annual installments beginning on March 1, 2017. |